Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Cost-utility Analysis

Cost-Utility Analysis in Health Research: Quality-Adjusted Life Years and Health Technology Assessment

Cost-utility analysis sets the cost of a treatment against a single measure intended to capture both the length and the quality of a patient’s life. This compression accounts for both the value of the method and the controversy surrounding it.

Pubrica AcademyWritten by a health-economics reviewer Reviewed bya biostatistician Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources1 peer-reviewed

Cost-utility analysis is a form of economic evaluation that compares the costs of alternative interventions against their outcomes expressed in quality-adjusted life years (QALYs), a single measure combining length of life and health-related quality of life, so that interventions targeting entirely different conditions can be compared on a common scale.

Learning objectives

  • Why cost-utility analysis uses QALYs rather than a disease-specific clinical outcome.
  • How a QALY is constructed from survival time and a quality-of-life weight.
  • What distinguishes cost-utility analysis from cost-effectiveness analysis more broadly.
  • Where the method is used in health-system decisions.

Common misconceptions

  • “Cost-utility analysis and cost-effectiveness analysis are the same thing.” Cost-effectiveness analysis is the broader category, comparing cost against any single clinical outcome measure; cost-utility analysis is specifically the form that uses QALYs, which are chosen because they permit comparison across different diseases and interventions on a single scale.
  • “A QALY is just a count of years survived.” A QALY weights each year of survival by a quality-of-life index, typically ranging from 0 (a state equivalent to death) to 1 (full health); ten years at a quality weight of 0.5 therefore contribute the same number of QALYs as five years at full health.

Rationale for QALYs rather than disease-specific outcomes

Drummond and colleagues, in their standard reference text on the economic evaluation of health care programmes, explain the rationale for cost-utility analysis directly: because QALYs combine survival and quality of life into one generic unit, a health system can compare the cost per QALY gained from a cancer therapy with the cost per QALY gained from a hip replacement or a mental health intervention, a comparison that a disease-specific outcome measure (tumour response, joint mobility score) cannot support across such different conditions.

Construction of a QALY

A QALY is calculated by multiplying the time spent in a health state by a utility weight for that state, where the weight is typically anchored between 0 (equivalent to death) and 1 (full health); some scales permit states judged worse than death to score below zero. These utility weights are usually derived from standardised preference-based instruments or population valuation studies, rather than from clinicians’ judgement of severity, specifically so that the weighting reflects how patients or the general population value different health states.

Applications of cost-utility analysis in health-system decisions

Health technology assessment bodies, including the UK National Institute for Health and Care Excellence (NICE), use cost-utility analysis, expressed as an incremental cost-effectiveness ratio in cost per QALY gained, as a central input to decisions about which treatments a health system should fund. This constitutes the methodological link between cost-utility analysis and the ICER, which is examined in a separate article on the incremental cost-effectiveness ratio: the QALY is the outcome unit, and the ICER is the ratio that decision-makers compare against a threshold.

Key points

Key points

Cost-utility analysis compares interventions by their cost per QALY gained, using QALYs specifically because they combine survival and quality of life into one generic unit that allows comparison across entirely different diseases and treatments, which is why health technology assessment bodies use it as a central input to funding decisions.

Practical application

Practical application

  1. State the utility-weight source explicitly. The preference-based instrument or valuation study used to derive quality-of-life weights should be named, rather than a QALY estimate being presented without disclosure of how its weights were obtained.
  2. QALYs should be reported alongside, not instead of, clinical outcomes. The underlying clinical outcome data should be presented together with the derived QALY estimate, so that readers can evaluate the utility-weighting choices rather than seeing only the aggregated final figure.
  3. The analysis should be matched to the decision it will inform. If the result is intended for a health technology assessment submission, the analysis and the reported ICER should be structured according to the specific methods guide of that body (such as that of NICE) rather than a generic template.

Frequently asked questions

Some preference-based scales permit health states valued as worse than death to score below zero, though this is less common than scores bounded between 0 and 1.

The underlying definition is consistent, but the specific valuation instrument and population used to derive utility weights can differ between studies and jurisdictions, which affects comparability.

Life-years gained does not account for quality of life during those years; a treatment that extends life in a very poor state of health and one that extends life in full health would score identically on life-years alone, a difference that QALYs are specifically designed to capture.

References

  1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015. read 10 October 2026. View on Oxford University Press

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Cost-Utility Analysis in Health Research: Quality-Adjusted Life Years and Health Technology Assessment. Pubrica. https://pubrica.com/academy/concepts-definitions/cost-utility-analysis/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Cost-utility analysis reporting stub

For use when reporting a cost-utility analysis in a manuscript or submission.

Comparator(s): ____
Utility-weight source/instrument: ____
Time horizon: ____
Discount rate applied (costs and outcomes): ____
Total QALYs per arm: ____
Total cost per arm: ____
Incremental cost per QALY gained: ____

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

The Pubrica health-economics team develops and reports cost-utility analyses to the standards expected by health technology assessment bodies, with utility-weight sources and discounting assumptions disclosed explicitly.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Cost-utility analysis for health technology assessment submissions

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.